Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Growth Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $742.15 (market cap $76.14B), while Vanguard Growth Index Fund ETF trades at $91.7 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 5.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| REGN | VUG | |
|---|---|---|
Market Cap | $76.14B | $384.60B |
Volume | 500,239 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $852.03 | $92.64 |
52-Week Low | $557.73 | $70.00 |
Typical Hold Time | 107 Days | 47 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
VUG trades at $92.42, down 0.24% on the day, with a bullish technical outlook supported by moving averages but showing overbought conditions on shorter-term RSI readings. The ETF maintains strong long-term performance credentials with 11-12% average annual returns since 2004, though current concentration in mega-cap tech stocks presents both opportunity and risk. Recent dividend activity shows minimal income generation with a $0.09 distribution scheduled for September 2026.
The growth-focused ETF offers exposure to market-leading companies but faces concentration risk with over 36% in three holdings. Long-term investors benefit from Vanguard's low-cost structure and historical outperformance, though near-term technical indicators suggest potential consolidation. Market sentiment remains positive for buy-and-hold strategies despite recent value stock outperformance in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
